LBL-034 not checked

Nanjing Leads Biolabs Co.,Ltd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Relapsed/Refractory Multiple Myeloma
Main trialPhase 1/2
“This trial is a single-arm, open-label, multicenter phase I/II clinical study of LBL-034 in patients with RRMM to evaluate the safety, tolerability, PK profile, immunogenicity and efficacy of LBL-034.”In the company’s words, NCT06049290 on ClinicalTrials.gov

Other drugs for Relapsed/Refractory Multiple Myeloma

All 133 drugs for Relapsed/Refractory Multiple Myeloma

Coming up1

Changes1

Last 90 days

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting 20 Sep 2029 A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow LBL-034

Following is part of Solo: you see every change to LBL-034 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in